[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome

Phase 2

Completed

• Conditions: Dry Eye Syndromes
• Interventions: Drug: KSR-001-04; Drug: KSR-001-03; Drug: KSR-001-02

• Registration Number: NCT05017844
• Lead Sponsor: Kukje Pharma

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of KSR-001 in patients with Dry Eye Syndrome

Detailed Description

Not available

Study Timeline

• Study Start: 2020-02-18
• Primary Completion: 2021-02-08
• Study Completion: 2021-06-22
• Status Verified: 2021-08
• Study First Submitted: 2021-08-19
• Study First Submitted QC: 2021-08-23
• Last Update Submitted: 2021-08-23
• Study First Posted: 2021-08-24
• Last Update Posted: 2021-08-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 222

Inclusion Criteria

1. Male and Female who over 19 years old

2. Those who have had symptoms of dry eye for at least 6 months (foreign body sensation, dryness, glare, pain pain, blurred vision, etc.) and Those whose symptoms do not improve with conservative treatment such as artificial tears

3. Those who meet below criteria at least one of two eyes

   • Those who have over than score 4 in corneal staining test
   • Tear secretion test without anesthesia(Schirmer test) result would be under 10mm/5min (If the test result is 0mm/5min, it should be over than 3mm/5min on the nasal stimulation schirmer test in the same eye)

4. both eyes, the corrected visual acuity is 0.2 or more

5. Written consent voluntarily to participate in this clinical trial

Exclusion Criteria

1. During this clinical trial period, When Rebamipide treatment is expected due to gastrointestinal disorder or gastritis

2. Within 90 days of the screening visit, if systemic steroid steroids or systemic immunosuppressants were used

3. Within 90 days of the screening visit, If there is a history of other ophthalmic surgeries including the use of punctum plugs or puncture closure surgery

4. If it is a clinically significant ophthalmic disease that is not caused by dry eye syndrome and may affect the interpretation of the results of this clinical trial

5. Within 90 days of the screening visit, Those who have undergone vision correction surgery such as LASIK or LASIK

6. Those with intraocular pressure (IOP) exceeding 21 mmHg or with glaucoma undergoing drug treatment

7. Those with hypersensitivity to the ingredient of this clinical trial drug

8. Patients planning to wear contact lenses during the clinical trial period

9. In the case of one of the following

   • Creatinine level more than twice the upper limit of normal range
   • AST or ALT levels greater than twice the upper limit of normal range

10. History of malignancy (except for cases where there has been no recurrence for more than 5 years after surgery)

11. Within 1 year before screening, Those who have been diagnosed with alcohol or drug abuse and are receiving treatment

12. In the case of women of childbearing potential, those who do not consent to contraception by a medically accepted method of contraception during the clinical trial period (IUD, Intrauterine device or IUS, Intrauterine system), tubal ligation, double blocking method (male condom, female condoms, cervical caps, contraceptive diaphragms, and Combination of blocking methods such as contraceptive sponges)

13. Pregnant or lactating women

14. within 30 days before participating in the clinical trial, Those who have applied other clinical trial drugs or medical devices

15. Patients judged by other investigators as unsuitable to participate in this clinical trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
KSR-001-04	KSR-001-04	KSR-001-04 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
KSR-001-03	KSR-001-03	KSR-001-03 eyedrops recieved one drop to both eyes four times a day for 12 weeks.
KSR-001-02	KSR-001-02	KSR-001-02 eyedrops recieved one drop to both eyes four times a day for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF)	Baseline, 12 weeks	FCS indicates the damage to the corneal epithelium. The degree of staining of the cornea after blue fluorescein staining under the slit lamp illumination of a cobalt blue light source was evaluated according to the National Eye Institute/Industry grading system.; Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated(0-15)(0 is better).

Secondary Outcome Measures

Name	Time	Method
Fluorescein Corneal Staining (FCS)	Baseline, 4 weeks, 8 weeks	The degree of staining of the cornea after blue fluorescein staining under the slit lamp illumination of a cobalt blue light source was evaluated according to the National Eye Institute/Industry grading system.
Lissamine Green Conjunctival Staining (LGCS)	Baseline, 4 weeks, 8 weeks, 12 weeks	After lysamine green staining under slit lamps, the conjunctival staining was evaluated according to the National Eye Institute/Industry grading system.
Ocular Surface Disease Index (OSDI)	Baseline, 4 weeks, 8 weeks, 12 weeks	The ocular surface disease index was assessed for ocular surface disease, including visual function (five items), eye symptoms (four items), and environmental factors (three items) , 0 point for none of the time, 1 point for some of the time, 2 points for half of the time, 3 points for most of the time, and 4 points for all of the time.
Unanesthetized Schirmer's test	Baseline, 4 weeks, 8 weeks, 12 weeks	After the eyes were wiped and the Schirmer test paper was inserted into the right eye at 1/3 of the lower eyelid without eye anesthesia and inserted into the left eye. After 5 minutes with the eyes closed, the Schirmer test paper was removed from the right side in the order of insertion and the left side removed. The wet length was measured in millimeters and the length of the midpoint was measured when the wet border was oblique.
Tear Film Break-up Time (TBUT)	Baseline, 4 weeks, 8 weeks, 12 weeks	After blinking blue fluorescein staining of the cobalt blue light source, it was observed from the blinking point that there was a black spot, a streak pattern or a fluorine defect in the fluorescein-tear layer Was measured in seconds. The measurement results were repeated three times and average values were used.

Trial Locations

Locations (1)

Kukje Pharma; 🇰🇷 Seongnam, Korea, Republic of